FDA Grants Accelerated Approval to T-DXd in Advanced HER2+ Solid Tumors
Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.
Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.
Learn how advanced basal cell carcinoma can be treated with a new combination radiation and drug therapy.
A preclinical study suggests that the addition of a component of the ketogenic diet—a preketone dietary supplement—to immunotherapy may potentially be effective in treating prostate…
53 receive Dean’s Impact Awards for teaching, guiding, inspiring, advocating
Scientific detective work helped transform a previously shelved drug into a medicine now approved for relapsed or progressive pediatric low-grade glioma.
Neli Ulrich, PhD, MS, of Huntsman Cancer Institute, has been awarded the 2024 Governor’s Medal for Science and Technology.
The role of a verification nurse can lead to several benefits, including the prevention of errors from reaching the patient, decreased workload, and potential cost…
The Lymphoma Research Foundation (LRF) offers a wide range of support services, for people with lymphoma and their loved ones.
Journal of Neuro-Oncology – The efficacy of systemic therapies for glioblastoma (GBM) remains limited due to the constraints of systemic toxicity and blood–brain barrier (BBB)…
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a…